Loading stock data…
LGND
$227.44-2.01 (-0.88%)
Market ClosedLast close May 1
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Ligand Pharmaceuticals Incorporated in the Healthcare sector is trading at $227.44. The stock is currently near its 52-week high of $247.38, remaining 21.6% above its 200-day moving average. Technical signals show neutral RSI of 59 and bearish MACD signal, explaining why LGND maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 59) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$227.44
Potential Downside
55.8%
Whystock Fair Value$100.57
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus10 analysts
Mean target$268.00+17.8%
Range$220.00 – $330.00
Fundamentals
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA an...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$4.58B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
37.33
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.00
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-7.46%
Volume
Today's trading volume
228,440
Recent News
Ligand Pharmaceuticals And 2 Other Stocks That May Be Trading At An Estimated Discount
Over the last 7 days, the United States market has remained flat, yet it is up 30% over the past year with earnings expected to grow by 16% per annum in the coming years. In this environment, identifying stocks that may be trading at an estimated discount can provide opportunities for investors seeking value amidst a generally rising market.
XOMA Royalty (XOMA) Moves 10.7% Higher: Will This Strength Last?
XOMA Royalty (XOMA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Ligand Pharmaceuticals to Buy XOMA Royalty for $39/Share, Lifts 2026 Guidance and EPS Outlook
Ligand Pharmaceuticals (NASDAQ:LGND) detailed plans to acquire XOMA Royalty Corporation in an investor call, outlining what executives described as a “highly complementary” transaction intended to expand Ligand’s royalty portfolio and accelerate growth. Under the definitive agreement, Ligand will pa
Royalty Powerhouse: Ligand And Xoma Unite In $739 Million Deal
Ligand Pharmaceuticals snatched up Xoma Royalty in a deal worth $739 million, the companies said Monday as both biotech stocks jumped.
Ligand Pharmaceuticals buying Xoma Royalty for $739 million
The all-cash deal adds more than 120 assets to Ligand's portfolio and is expected to close in the third quarter of 2026